SCHEMBL7289255

SCHEMBL7289255

[CH]=CCCCC/C=C/CCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.42
TRPV1 Q8NER1 2/20 0.42
TERT O14746 3/20 0.37
CYP1A2 P05177 2/20 0.37
MAPT P10636 2/20 0.37
CYP2C19 P33261 2/20 0.37
BLM P54132 2/20 0.37
HSD17B10 Q99714 2/20 0.37
FABP4 P15090 2/20 0.37
F7 P08709 2/20 0.37
F3 P13726 2/20 0.37
PTPN1 P18031 2/20 0.37
PPARG P37231 2/20 0.37
KMT2A Q03164 2/20 0.37
PPARD Q03181 2/20 0.37
PPARA Q07869 2/20 0.37
GMNN O75496 1/20 0.37
USP2 O75604 1/20 0.37
LMNA P02545 1/20 0.37
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7289260 1.00 FAAH (0.42) FAAHTRPV1TERTCYP1A2MAPT
SCHEMBL28731019 0.97 FAAH (0.46) FAAHTRPV1TERTCYP1A2MAPT
SCHEMBL25178125 0.97 FAAH (0.46) FAAHTRPV1TERTCYP1A2MAPT
SCHEMBL29284435 0.97 FAAH (0.41) FAAHTRPV1TERTCYP1A2MAPT
SCHEMBL25185950 0.97 FAAH (0.46) FAAHTRPV1TERTCYP1A2MAPT
SCHEMBL25181812 0.97 FAAH (0.46) FAAHTRPV1TERTCYP1A2MAPT
SCHEMBL29284541 0.97 FAAH (0.46) FAAHTRPV1TERTCYP1A2MAPT
SCHEMBL21694548 0.97 FAAH (0.46) FAAHTRPV1TERTCYP1A2MAPT
SCHEMBL21694546 0.97 FAAH (0.46) FAAHTRPV1TERTCYP1A2MAPT
SCHEMBL147359 0.94 TRPV1 (0.38) FAAHTRPV1TERTCYP1A2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12031130-B2 Composition for modifying target gene TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-07-09 US disclosed
US-11993570-B2 Cationic lipids TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-05-28 US disclosed
EP-3733641-B1 CATIONIC LIPIDS TAKEDA PHARMACEUTICALS CO (JP) 2024-04-10 EP disclosed
CN-111511713-B Cationic lipid 武田药品工业株式会社 2024-01-02 CN disclosed
CN-111527204-B Composition for target gene modification 国立大学法人京都大学 2023-09-01 CN disclosed
US-20230257338-A1 CATIONIC LIPIDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-08-17 US disclosed
US-20210371854-A1 COMPOSITION FOR MODIFYING TARGET GENE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-12-02 US disclosed
EP-3733844-A1 COMPOSITION FOR MODIFYING TARGET GENE Kyoto University (JP) 2020-11-04 EP disclosed
EP-3733641-A1 CATIONIC LIPIDS Takeda Pharmaceutical Company Limited (JP) 2020-11-04 EP disclosed
US-20200331841-A1 CATIONIC LIPIDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-10-22 US disclosed
US-5786367-A OXYGEN SCAVENGERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1998-07-28 US disclosed
EP-0719258-A1 CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1996-07-03 EP disclosed
WO-1996002508-A1 CYCLIC AMIDE DERIVATIVES FOR PROTECTING AGAINST ULTRAVIOLET RAYS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1996-02-01 WO disclosed
US-5306719-A Cardiotonic agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-04-26 US disclosed
EP-0255134-B1 CARBOSTYRIL DERIVATIVES AND SALTS THEREOF, PROCESS FOR PREPARING THEM, AND CARDIOTONIC COMPOSITION CONTAINING SAME OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-03-03 EP disclosed
US-5071856-A CARBOSTYRIL DERIVATIVES AND SALTS THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1991-12-10 US disclosed
US-4886809-A CARDIOTONIC AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-12-12 US disclosed
US-4845100-A WITH HYPOTENSIVE AND ANTIINFLAMMATORY ACTIVITY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-07-04 US disclosed
EP-0255134-A2 Carbostyril derivatives and salts thereof, process for preparing them, and cardiotonic composition containing same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1988-02-03 EP disclosed
EP-0202760-A2 Carbostyril derivatives and salts thereof, processes for preparing the same and cardiotonic composition containing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11993570-B2 Cationic lipids ELOVL5, LPCAT3, ELOVL3 FAAH 1807/4885TRPV1 1432/4885TERT 622/4885
US-20210371854-A1 COMPOSITION FOR MODIFYING TARGET GENE NSUN2, NSUN3, RNASE1 FAAH 3436/4885TRPV1 4572/4885TERT 1942/4885
US-12031130-B2 Composition for modifying target gene NSUN2, NSUN3, RNASE1 FAAH 3436/4885TRPV1 4572/4885TERT 1942/4885
US-20230257338-A1 CATIONIC LIPIDS ELOVL5, LPCAT3, ELOVL3 FAAH 1807/4885TRPV1 1432/4885TERT 622/4885
US-20200331841-A1 CATIONIC LIPIDS ELOVL5, LPCAT3, ELOVL3 FAAH 1807/4885TRPV1 1432/4885TERT 622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.